Articles les plus consultés

  • Les futures sur cac belle glissade < vix pas bon + 3%
        francis 13 Version sans publicité Marchés   Actualités   Analyses   Crypto   Fonds   Graphiques   Technique   Brokers   Outils   Portefe...
  • Nouvelles applications de médicaments avec des documents de soutien
    6% Hydroxyethyl Starch 130 / 0.4 in 0.9% Injection de chlorure de sodium (Voluven 500 mL freeflex flexible en plastique intraveineuse solut...
  • pre-market
    Top Gaining Stocks % Chg Dernier Symb Compagnie Le volume 16,22% 2.15 SRNE Sorrento Therapeut 7030 10,92% 2,64 CIE Cobalt Inte...
  • pre-market
    Pre Market Top Gainers prénom Dernier Chg. % Vol. Iridium   14.95 + 39.07% 0,60K Mondialisation de l'Inde.   0,4800 + 18,52% 1,80K...
  • pre-market
    Pre Market Top Gainers prénom Dernier Chg. % Vol. Oracle Corporation   51.30 + 10,73% 58.90K Staples Inc   9.25 + 6,81% 12,31K Delcat...
  • pre_market
    Pre Market Top Gainers prénom Dernier Chg. % Vol. Delcath   0.1230 + 24,24% 196,67K Neos Therapeutics I.   10.50 +16.67% 34.36K Enpha...
  • les élus
    Citoyens_Français ‏   @citoyenneFrance     8 juin Plus Attali : « Les élus n’ont plus de pouvoir et voici votre avenir » - Effr......
  • pre-market
    Pre Market Top Gainers prénom Dernier Chg. % Vol. Lipocine In   5.32 + 32,34% 38.64K Enphase Energy Inc   0,938 + 17,57% 10,37K Delca...
  • bonjour.. approbations
    28 juin 2017 Nom du médicament et  numéro de demande Ingrédient actif Formulaire de posologie / itinéraire Soumission Compagnie ...
  • $ pré-market
    Plus fortes hausses en préouverture Nom Dernier Var.% Vol. DragonWave Inc   1,3900 +25,23% 3,55K Alibaba   139,95 +11,35% 1,40M MoSys...

mercredi 4 avril 2018

INVENTIVA Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes

INVENTIVA Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes
Posted by at Aucun commentaire:

CURE Media Group Expands Strategic Alliance Partnership Program with the Head and Neck Cancer Alliance | Business Wire

CURE Media Group Expands Strategic Alliance Partnership Program with the Head and Neck Cancer Alliance | Business Wire: CURE Media Group Expands Strategic Alliance Partnership Program with the Head and Neck Cancer Alliance
Posted by at Aucun commentaire:

Humana Announced as Exclusive Arizona, California, Nevada and Washington Health Plan Sponsor for National Senior Health & Fitness Day®, May 30 | Business Wire

Humana Announced as Exclusive Arizona, California, Nevada and Washington Health Plan Sponsor for National Senior Health & Fitness Day®, May 30 | Business Wire: Humana announced as exclusive Arizona, California, Nevada and Washington health plan sponsor for National Senior Health & Fitness Day, May 30.
Posted by at Aucun commentaire:

Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril

Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril
Posted by at Aucun commentaire:

Acupression pour la douleur menstruelle | EurekAlert! Nouvelles scientifiques

Acupression pour la douleur menstruelle | EurekAlert! Nouvelles scientifiques: Can acupressure achieve a sustained reduction in menstrual pain? Is an app-based self-care program particularly attractive to young women? These questions addressed in a new study by researchers from Charité - Universitätsmedizin Berlin, the results of which have been published in the American Journal of Obstetrics and Gynecology*.
Posted by at Aucun commentaire:

MJ Biotech, Inc Announces $428,000 in First Quarters Sales

MJ Biotech, Inc Announces $428,000 in First Quarters Sales
Posted by at Aucun commentaire:

Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer

Cellectar Biosciences Appoints Brian M. Posner as Chief Financial Officer
Posted by at Aucun commentaire:
Inscription à : Articles (Atom)